1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 75, 2024
  5. Article

Annual Review of Medicine

Volume 75, 2024

Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors

Abstract

Antibody-drug conjugates (ADCs) have become the cornerstone of effective therapeutics in solid and hematological malignancies by harnessing potent cytotoxic payloads with targeted tumoricidal delivery. Since the monumental shift occurred with HER2-targeted ADCs, the discovery of the TROP2 antigen has revolutionized the landscape of ADC development. Moving beyond the traditional ADC design, multiple novel ADCs have successfully shaped and improved survival outcomes in patients with various tumor histologies. Here we review and contrast the clinical impact of the well-known TROP2 ADCs currently in clinical use. We also shed light on upcoming investigational TROP2 ADCs showing promise with novel ADC platforms.

Keyword(s): ADC, antibody-drug conjugates, datopotamab, sacituzumab, TROP2
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-071322-065903
2024-01-29
2024-05-06
Loading full text...

Full text loading...

/deliver/fulltext/med/75/1/annurev-med-071322-065903.html?itemId=/content/journals/10.1146/annurev-med-071322-065903&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Lipinski M, Parks DR, Rouse RV, Herzenberg LA. 1981. Human trophoblast cell-surface antigens defined by monoclonal antibodies. PNAS 78:5147–50
     [Google Scholar]
  2. 2.
    Bignotti E, Todeschini P, Calza S et al. 2010. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur. J. Cancer 46:944–53
     [Google Scholar]
  3. 3.
    Fornaro M, Dell'Arciprete R, Stella M et al. 1995. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int. J. Cancer 62:610–18
     [Google Scholar]
  4. 4.
    Liu X, Deng J, Yuan Y et al. 2022. Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer. Pharmacol. Ther. 239:108296
     [Google Scholar]
  5. 5.
    Tsukahara Y, Tanaka M, Miyajima A. 2011. TROP2 expressed in the trunk of the ureteric duct regulates branching morphogenesis during kidney development. PLOS ONE 6:e28607
     [Google Scholar]
  6. 6.
    Wang J, Day R, Dong Y et al. 2008. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol. Cancer Ther. 7:280–85
     [Google Scholar]
  7. 7.
    Bardia A, Mayer IA, Vahdat LT et al. 2019. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N. Engl. J. Med. 380:741–51
     [Google Scholar]
  8. 8.
    Alberti S, Miotti S, Stella M et al. 1992. Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma 11:539–45
     [Google Scholar]
  9. 9.
    Stein R, Basu A, Chen S et al. 1993. Specificity and properties of MAb RS7–3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int. J. Cancer 55:938–46
     [Google Scholar]
  10. 10.
    Zhang L, Zhou W, Velculescu VE et al. 1997. Gene expression profiles in normal and cancer cells. Science 276:1268–72
     [Google Scholar]
  11. 11.
    Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL et al. 2002. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am. J. Pathol. 160:1239–49
     [Google Scholar]
  12. 12.
    Nakashima K, Shimada H, Ochiai T et al. 2004. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int. J. Cancer 112:1029–35
     [Google Scholar]
  13. 13.
    Birkenkamp-Demtroder K, Olesen SH, Sørensen FB et al. 2005. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 54:374–84
     [Google Scholar]
  14. 14.
    Shvartsur A, Bonavida B. 2015. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer 6:84–105
     [Google Scholar]
  15. 15.
    Stepan LP, Trueblood ES, Hale K et al. 2011. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J. Histochem. Cytochem. 59:701–10
     [Google Scholar]
  16. 16.
    Zeng P, Chen MB, Zhou LN et al. 2016. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci. Rep. 6:33658
     [Google Scholar]
  17. 17.
    Cardillo TM, Govindan SV, Sharkey RM et al. 2011. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin. Cancer Res. 17:3157–69
     [Google Scholar]
  18. 18.
    Shastry M, Jacob S, Rugo HS, Hamilton E. 2022. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. Breast 66:169–77
     [Google Scholar]
  19. 19.
    Bardia A, Messersmith WA, Kio EA et al. 2021. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132–01 basket trial. Ann. Oncol. 32:746–56
     [Google Scholar]
  20. 20.
    Bardia A, Hurvitz SA, Tolaney SM et al. 2021. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384:1529–41
     [Google Scholar]
  21. 21.
    FDA 2023. Prescribing information for Trodelvy. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf
  22. 22.
    Tagawa ST, Balar AV, Petrylak DP et al. 2021. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J. Clin. Oncol. 39:2474
     [Google Scholar]
  23. 23.
    Petrylak DP, Jain RK, Bupathi M et al. 2023. Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy Poster presented at American Society of Clinical Oncology Genitourinary Symposium Feb. 16 San Francisco, CA:
  24. 24.
    Heist RS, Guarino MJ, Masters G et al. 2017. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J. Clin. Oncol. 35:2790
     [Google Scholar]
  25. 25.
    Santin A, Komiya T, Goldenberg DM et al. 2020. Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study. J. Clin. Oncol. 38:15 Suppl.6081
     [Google Scholar]
  26. 26.
    Brenner AJ, Pandey R, Chiou J et al. 2021. Abstract PD13–05: delivery and activity of SN-38 by sacituzumab govitecan in breast cancer brain metastases. Cancer Res. 81:PD13–05
     [Google Scholar]
  27. 27.
    Spring L, Tolaney SM, Desai NV et al. 2022. Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: results from the NeoSTAR trial. J. Clin. Oncol. 40:16 Suppl.512
     [Google Scholar]
  28. 28.
    Marmé F, Hanusch C, Furlanetto J et al. 2022. 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment. Ann. Oncol. 33:S148–49
     [Google Scholar]
  29. 29.
    Okajima D, Yasuda S, Maejima T et al. 2021. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol. Cancer Ther. 20:2329–40
     [Google Scholar]
  30. 30.
    Ocean AJ, Starodub AN, Bardia A et al. 2017. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer 123:3843–54
     [Google Scholar]
  31. 31.
    Aditya Bardia M, Krop I, Meric-Bernstam F et al. 2022. Datopotamab deruxtecan (Dato-DXd) in advanced triple-negative breast cancer (TNBC): updated results from the phase 1TROPION-PanTumor01 Study Poster presented at San Antonio Breast Cancer Symposium Dec. 6 San Antonio, TX:
  32. 32.
    Meric-Bernstam F, Juric D, Kogawa T et al. 2022. Phase 1 TROPION-PanTumor01 study evaluating datopotamab deruxtecan (Dato-DXd) in unresectable or metastatic hormone receptor–positive/HER2-negative breast cancer Paper presented at SABCS (San Antonio Breast Cancer Symposium) December 6th, 2022 San Antonio, Texas, USA:
  33. 33.
    Shimizu T, Sands J, Yoh K et al. 2023. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan in non–small-cell lung cancer: TROPION-PanTumor01. J. Thorac. Oncol. 16:S106–7
     [Google Scholar]
  34. 34.
    Garon EB, Lisberg AE, Spira A et al. 2021. Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): preliminary results from the phase I TROPION-PanTumor01 study Oral session presented at European Society of Medical Oncology Congress Sep. 16 Lugano, Switz.:
  35. 35.
    Meric-Bernstam F, Spira AI, Lisberg AE et al. 2021. TROPION-PanTumor01: dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 39:15 Suppl.9058
     [Google Scholar]
  36. 36.
    Abuhelwa Z, Alloghbi A, Alqahtani A, Nagasaka M. 2022. Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs 82:979–87
     [Google Scholar]
  37. 37.
    Abelman RO, Ryan PK, Fell G et al. 2023. Association between stomatitis and treatment efficacy with novel TROP2-directed antibody drug conjugate (ADC), datopotamab deruxtecan, in patients with metastatic cancer Paper presented at Annual Meeting of the American Association for Cancer Research Apr. 14 Orlando, FL:
  38. 38.
    Rodon J, Li J, Xue J et al. 2021. An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors. Ann. Oncol. 32:S585
     [Google Scholar]
  39. 39.
    Yongmei Yin XW, Ouyang Q, Yan M et al. 2022. Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in phase 2 study Paper presented at San Antonio Breast Cancer Symposium Dec. 6 San Antonio, TX:
  40. 40.
    Strop P, Tran TT, Dorywalska M et al. 2016. RN927C, a site-specific Trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models. Mol. Cancer Ther. 15:2698–708
     [Google Scholar]
  41. 41.
    King GT, Eaton KD, Beagle BR et al. 2018. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Investig. New Drugs 36:836–47
     [Google Scholar]
  42. 42.
    Mei X, Tang W, Zhou X et al. 2023. Abstract P4-01-32: BAT8008, a novel Trop-2 ADC with strong bystander effect, for the treatment of Trop-2 positive cancer. Cancer Res. 83:P4–01-32-P4-01-32
     [Google Scholar]
  43. 43.
    Zhang Y, Li B, Shi R et al. 2022. The Trop-2-targeting antibody drug conjugate DB-1305 has higher antitumor activity and a potentially better safety profile compared with DS-1062. Eur. J. Cancer 174:S91–92
     [Google Scholar]
  44. 44.
    Nicolò E, Giugliano F, Ascione L et al. 2022. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat. Rev. 106:102395
     [Google Scholar]
  45. 45.
    Cardillo TM, Sharkey RM, Rossi DL et al. 2017. Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer. Clin. Cancer Res. 23:3405–15
     [Google Scholar]
  46. 46.
    Petros Grivas DP, Park CH, Barthelemy P et al. 2023. Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy Paper presented at American Society of Clinical Oncology Genitourinary Symposium Feb. 16 San Francisco, CA:
  47. 47.
    Jain RK, Yang Y, Chadha J, Chatwal MS et al. 2023. Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma Paper presented at American Society of Clinical Oncology Genitourinary Symposium Feb. 16 San Francisco, CA:
  48. 48.
    Bardia A, Coates JT, Spring L et al. 2022. Sacituzumab govitecan, combination with PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer (TNBC): translational investigation. Cancer Res. 82:2638 Abstr. )
     [Google Scholar]
  49. 49.
    Bardia A, Spring LM, Juric D et al. 2020. 358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer. Ann. Oncol. 31:S394
     [Google Scholar]
  50. 50.
    Yap TA, Hamilton E, Bauer T et al. 2022. Phase Ib SEASTAR study: combining rucaparib and sacituzumab govitecan in patients with cancer with or without mutations in homologous recombination repair genes. JCO Precis. Oncol. 6:e2100456
     [Google Scholar]
  51. 51.
    Schmid P, Ma CX, Park YH et al. 2022. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study Paper presented at San Antonio Breast Cancer Symposium Dec. 6 San Antonio, Texas, USA:
  52. 52.
    Levy B, Paz-Ares L, Rixe O et al. 2022. TROPION-Lung02: initial results from datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC Paper presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer Aug. 6–9 Vienna, Austria:
  53. 53.
    Yuca E, Evans K, Akcakanat A et al. 2022. Anti-tumor activity and biomarker analysis for datopotamab deruxtecan in breast cancer PDX models. Cancer Res. 82:1768 Abstr. )
     [Google Scholar]
  54. 54.
    Yap TA, Im S-A, Schram AM et al. 2022. PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations. Cancer Res. 82:CT007 Abstr. )
     [Google Scholar]
  55. 55.
    Hopkins TA, Ainsworth WB, Ellis PA et al. 2019. PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow. Mol. Cancer Res. 17:409–19
     [Google Scholar]
  56. 56.
    Farrés J, Martín-Caballero J, Martínez C et al. 2013. Parp-2 is required to maintain hematopoiesis following sublethal γ-irradiation in mice. Blood 122:44–54
     [Google Scholar]
  57. 57.
    Shee K, Wells JD, Jiang A, Miller TW. 2019. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy. PLOS ONE 14:e0224267
     [Google Scholar]
  58. 58.
    Cardillo TM, Mostafa AA, Rossi DL et al. 2017. Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51. Cancer Res. 77:Suppl. 133193
     [Google Scholar]
  59. 59.
    Coussy F, El-Botty R, Château-Joubert S et al. 2020. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Sci. Transl. Med. 12:eaax2625
     [Google Scholar]
  60. 60.
    Bardia A, Tolaney SM, Punie K et al. 2021. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann. Oncol. 32:1148–56
     [Google Scholar]
  61. 61.
    Schmid P, Cortés J, Marmé F et al. 2022. Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study. Ann. Oncol. 33:S635–36
     [Google Scholar]
  62. 62.
    Rugo MH, Bardia A, Marmé F et al. 2022. GS1-11 sacituzumab govitecan (SG) versus treatment of physician's choice(TPC): efficacy by Trop-2 expression in the TROPiCS-02 study of patients (Pts) with HR+/HER2− metastatic breast cancer (mBC) Paper presented at San Antonio Breast Cancer Symposium Dec. 6 San Antonio, TX:
     [Google Scholar]
  63. 63.
    Coates JT, Sun S, Leshchiner I et al. 2021. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 11:2436–45
     [Google Scholar]
/content/journals/10.1146/annurev-med-071322-065903
Loading
Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors
Annual Review of Medicine 75, 31 (2024); https://doi.org/10.1146/annurev-med-071322-065903
/content/journals/10.1146/annurev-med-071322-065903
/content/journals/10.1146/annurev-med-071322-065903
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error